Septal ablation in hypertrophic cardiomyopathy: Current status;Ablación septal en la miocardiopatía hipertrófica: Situación actual

Revista Espanola de Cardiologia

Volumn 56, Issue 12, 2003, Pages 1153-1159

  Seggewiss, Hubert ^a   Rigopoulos, Angelos ^b  

^a Leopoldina Krankenhaus   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ECHOCARDIOGRAPHY; EDITORIAL; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 1642554529     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13055331     Document Type: Editorial

References (52)

1. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995;92:1680-92.
2. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336: 775-85.
3. Frank MJ, Abdulla AM, Canedo MI, Saylors RE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 1978;42:993-1001.
4. Haberer T, Hess OM, Jenni R, Krayenbühl HP. Hypertrophic obstructive cardiomyopathy: Spontaneous course in comparison to long-term therapy with propanolol and verapamil. Z Kardiol 1983;72:487-93.
5. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross Jr J. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964;29:84-98.
6. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979;42:35-42.
7. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982;307:997-9.
8. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 1993;125:1691-7.
9. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment? J Am Coll Cardiol 1996;27:431-2.
10. Schulte HD, Gramsch-Zabel H, Schwartzkopff B. Hypertrophe obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wschr 1995;125:1940-9.
11. Robbins RC, Stinson EB, Daily PO. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111:586-94.
12. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995;110:195-208.
13. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995;92(Suppl II):122-7.
14. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435-41.
15. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927-33.
16. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing in cardiomyopathy. Am J Cardiol 1999;83:903-7.
17. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2001;3: 160-6.
18. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
19. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997;18:846-51.
20. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-8.
21. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute and 3-months follow-up results with respect to myocardial contrast echocardiography. Circulation 1998;98: 2415-21.
22. Faber L, Seggewiss H, Fassbender D, et al. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography. J Interv Cardiol 1998;11:443-8.
23. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-5.
24. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
25. Seggewiss H, Faber L, Meyners W, Bogunovic N, Odenthal HJ, Gleichmann U. Simultaneous percutaneous treatment in hypertrophic obstructive cardiomyopathy and coronary artery disease: a case report. Cathet Cardiovsac Diagn 1998;44:65-9.
26. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81.
27. Lakkis N, Kleiman N, Killip D, Spencer WH 3rd. Hypertrophic obstructive cardiomyopathy: alternative therapeutic options. Clin Cardiol 1997;20:417-8.
28. Bhargava B, Agarwal R, Kaul U, Manchanda SC, Wasir HS. Transcatheter alcohol ablation of the septum in a patient of hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diagn 1997;41:56-8.
29. Kornacewicz-Jach Z, Gil R, Wojtarowicz A, et al. Early results of alcohol ablation of the septal branch of coronary artery in patients with hypertrophic obstructive cardiomyopathy. Kardiol Pol 1998; 48:105-12.
30. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA, et al. Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998;32:225-9.
31. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342-54.
32. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
33. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000;83:326-31.
34. Ruzyllo W, Chojnowska L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:770-7.
35. Seggewiss H, Faber L, Ziemssen P, Meyners W, Krater L, Meissner A, et al. Age related acute results in percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2000;35(Suppl A):A188.
36. Seggewiss H, Faber L, Ziemssen P, Meyners W. Non-surgical septal ablation (PTSMA) in patients with NYHA class IV and hypertrophic obstructive cardiomyopathy (HOCM) [abstract]. Circulation 1999;100(Suppl I):515.
37. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 2001;76:799-802.
38. Seggewiss H, Faber L. Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr 2000;1:277-80.
39. Kern MJ, Holmes DG, Simpson C, Bitar SR, Rajjoub H. Delayed occurrence of complete heart block without warning after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Interv 2002;56:503-7.
40. Faber L, Seggewiss H, Werlemann BC, Fassbender D, Schmidt HK, Horstkotte D. Prediction of the risk of pacemaker dependency after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2002;39(Suppl A):845-3.
41. Welge D, Faber L, Werlemann BC, Krater L, Seggewiss H, Gleichmann U, et al. Long-term outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2002;39:A845.
42. Ziemssen P, Faber L, Schlichting J, Meyners W, Horstkotte D, Seggewiss H. Percutaneous septa] ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity. J Am Coll Cardiol 2000,35:A182.
43. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:846-53.
44. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
45. Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 1989; 76:255-63.
46. Seggewiss H, Faber L, Ziemssen P, Gleichmann U. One year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr 2001;126:424-30.
47. Seggewiss H, Faber L, Kleikamp G, Becker J, Gleichmann U. Hypertrophic obstructive cardiomyopathy and coronary artery disease: surgical or interventional therapy. Eur Heart J 1998; 19(Suppl):624.
48. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38: 1994-2000.
49. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-6.
50. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise aoutcomes. Eur Heart J 2002;23:1617-24.
51. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation 2002;106:454-9.
52. Kuhn H, Gietzen FH, Leuner C, Schafers M, Schober O, Strunk-Muller C, et al. Transcoronary ablation of septal hypertrophy: a new treatment for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000;89(Suppl 4):41-54.